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Differential scanning calorimeterAs a part of our ongoing program of developing novel inﬂuenza virus inhibitors, some new derivatives of
oseltamivir were prepared by modifying the amino group with glycyl, acetyl, benzyl and prolyl moieties. The
interactions of these derivatives with neuraminidase have been probed by molecular modeling techniques.
Further, the interaction of these derivatives with model membranes prepared from DPPC and the effect on
the thermotropic behavior and polymorphism of the bilayers have been investigated by multinuclear NMR
and DSC methods. Results indicate that the glycyl derivative of oseltamivir has the most profound effects on
the membrane, compared to other derivatives and seems to be the most promising derivative for further
pharmacological evaluation as a neuraminidase inhibitor.© 2009 Elsevier B.V. All rights reserved.1. Introduction
The highly pathogenic H5N1 inﬂuenza virus remains a constant
threat due to its high fatality and resistance to the commercially
available drugs [1,2]. The inﬂuenza virus contains two surface
glycoproteins — hemagglutinin (HA) and neuraminidase (NA) [3].
Sixteen subtypes of HA (H1 toH16) andnine subtypes of NA (N1 toN9)
have been presently identiﬁed [4]. HA is responsible for the binding of
the virus to the target cells via the terminal sialic acid residue in
glycoconjugates. On the other hand, NA catalyzes the removal of the
terminal sialic acid linked to glycoproteins and glycolipids. It has been
postulated that NA is necessary for the elution of the newly formed
viruses from infected cells since it digests sialic acid in the HA receptor
[5]. Its role in inﬂuenza virus replication means that inhibition of NA
will delay the release of progeny virus from the surface of infected cells,
thereby suppressing the viral growth. In viewof this, NAhas becomean
attractive target for developing drugs against the inﬂuenza virus [6].
The NA inhibitors currently in the market are oseltamivir (GS-
4104) [7] and zanamivir (GG-167) [8]. The last mentioned drug due to
its high polarity, is administered by inhalation. GS-4104 [Ethyl-(3R,
4R, 5S)-(1-ethylpropyloxy)-4-acetamido-5-amino-1-cyclohexene-1-
carboxylate)] is an ethyl ester prodrug which is hydrolyzed in vivo
to the active form oseltamivir carboxylate (GS-4071) [9]. GS-4071 has
poor oral bioavailability (less than 5% in rats) [10]; on the other hand,ll rights reserved.the prodrug GS-4104 being more hydrophobic has better bioavail-
ability. The prodrug is sold as the phosphate salt and is orally
administered [11]. Studies that throw light on the interaction of the
prodrug GS-4104 with model membranes will provide some under-
standing of the absorption and the transport of the drug through the
gastrointestinal tract. However, the antiviral activity ensues from the
interaction of the parent drug (GS-4071) with the neuraminidase
receptor and this aspect can be understood by carrying out docking of
GS-4071 with its receptor. Mutations in the active site of NA are
responsible for the development of resistance to oseltamivir [12,13].
However, such a resistance has not been observed for zanamivir [14].
Molecular docking is a useful tool to investigate the ligand–
enzyme interactions [15] providing ideas on the design and develop-
ment of new NA inhibitors. From molecular docking studies of
oseltamivir (GS-4071) and zanamivir (GG-167) to the neuraminidase
enzyme, it has been proposed that the introduction of substituents at
the amino group of oseltamivir may help in tighter binding to NA,
thereby decreasing resistance [16]. Based on this suggestion, we have
prepared derivatives of oseltamivir (GS-4104) (OS) with varying
charge and lipophilicity, by substituting glycyl (OS-gly), acetyl (OS-
ac), benzyl (OS-bz) and prolyl (OS-pro) groups at the amino group of
oseltamivir. To understand the effect of these groups on the binding of
the derivatives to the neuraminidase enzyme, the parent compound
and its derivatives were docked into the H5N1-NA active site by
molecular docking methods and their binding energies analyzed.
NA inhibitors are also known to interferewith HA receptor binding,
limiting the ability of HA to promote attachment and fusion of the cell
Scheme 1.
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cell fusion also affect the entry of the virus into the immune cells. Cell–
cell fusion involves a fusion of the membrane of the cells, and some
aspects of this process can be modeled by bilayers prepared from a
variety of synthetic andnatural lipids. In order to gain some insight into
how NA inhibitors affect cell–cell fusion, we have investigated the
effect of these derivatives on the changes in the thermotropic
properties and organization of membrane bilayers prepared from
model membranes, by multinuclear and multidimensional nuclear
magnetic resonance (NMR) and differential scanning calorimetric
(DSC) techniques. The results have been further supported by
transmission electron microscopic (TEM) studies. These studies
provide detailed information on the effect of the drug on the lipid
head group and the conformation and dynamics of the hydrophobic
chain [19]. Further, we hope that these studieswill help us to select the
best derivative that could be taken up for biological evaluation.
2. Materials and methods
2.1. Materials
Oseltamivir phosphate was a gift from Cipla Ltd, India. L-α-
dipalmitoyl phosphatidyl choline (DPPC) was purchased from SigmaSchemeChemical Co., USA. Boc-glycine, Boc-proline and 1,3-dicyclohexylcar-
bodiimide (DCC) were obtained from Spectrochem, India and
triﬂuoroacetic acid (TFA) was obtained from Merck, India. All other
solvents used in the synthesis were of LR grade.
2.2. NMR experiments
NMR experiments were recorded on a BRUKER AVANCE 500 MHz
NMR spectrometer. 2D-COSY (Correlation spectroscopy), NOESY
(Nuclear Overhauser effect spectroscopy), TOCSY (Total correlation
spectroscopy) and ROESY (Rotating frame Overhauser effect spectro-
scopy) spectra were recorded using standard pulse programs [20–23].
31P and 13C NMR experiments were carried out with a relaxation delay
of 1 s and broadband proton decoupling. The NMR datawas processed
with Topspin 2.1.
2.3. DSC experiments
DSC measurements were carried out on the differential scanning
calorimeter VP-DSC (MicroCal, Northampton MA, USA). The samples
were degassed under vacuum before being loaded into the reference
and sample cells. A scan rate of 10 °C/h was employed. Data was
analyzed with the software ORIGIN provided by MicroCal. All the2.
Fig. 1. Molecular structure of oseltamivir (GS-4104) and its derivatives.
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Repeated scans for the same sample were generally superimposable.
2.4. Sample preparation for NMR and DSC experiments
Multilamellar vesicles (MLV) were prepared by the standard
procedure [24] wherein the desired quantity of DPPC was dissolved
in chloroform. The solvent was then evaporated with a stream of
nitrogen so as to deposit a lipid ﬁlm on the walls of the container. The
last traces of the solvent were removed with vacuum for a period of
1 h. The lipid ﬁlmwas hydratedwith the required amount of a solution
of oseltamivir (GS-4104) or its derivatives in D2O; this was then
incubated in a water bath at 50 °C with repeated vortexing. The lipid
concentrations were maintained at 100 mM for the NMR and 50 mMTable 1
1H and 13C chemical shifts (ppm) for oseltamivir (GS-4104) (OS) and its derivatives.
Assignment Oseltamivir (D2O) OS-gly (CDCl3) OS-ac
1H 13C 1H 13C 1H
2 6.76 139.09 6.7 137.97 6.76
3 4.25 75.24 4.16 75.43 4.2
8 4.17 62.22 4.12 60.76 4.17
4 3.97 52.87 3.90 54.71 4.1
5 3.46 49.33 4.13 48.62 4.0
10 3.51 84.33 3.33 82.26 3.37
6a 2.88 28.33 2.67 30.14 2.73
6b 2.45 28.33 2.22 30.14 2.20
16 2.0 22.60 1.9 22.83 2.0
11 1.5 25.69 1.46 26.08 1.51
13 1.48 25.31 1.42 25.48 1.47
9 1.20 13.50 1.25 13.82 1.27
12 0.80 8.64 0.86 9.23 0.86
14 0.76 8.74 0.80 8.84 0.81
1 127.82 128.41
7 175.45 172.31
15 167.62 165.88
17 166.36
18 3.78 40.86 2.0
19
20
21
22
23
1′ 7.56 6.55
2′ 8.15 6.0
3′ 8.15for the DSC experiments. Unilamellar vesicles (ULV) were prepared by
sonicating the above dispersions with a Branson sonicator (Model
450) at 50% duty cycles till the solution was optically clear.
2.5. Determination of MLV-drug (oseltamivir and its derivatives) binding
Binding constants were determined by the centrifugation method
as previously described [25]. Optical density of a 100 μM solution of
the drug molecule was measured with a spectrophotometer. MLVs
were prepared by varying lipid concentration systematically from
0.25 mg/2.0 ml to 2.0 mg/2.0 ml and ﬁxed drug concentration of
100 μM (giving rise a drug:lipid ratio 1:2.5 to 1:20) as described in the
previous section. The resulting solutions were incubated for 2 h and
subsequently transferred into ultracentrifuge tubes. Separation of(CDCl3) OS-bz (MeOD) OS-pro (CDCl3)
13C 1H 13C 1H 13C
137.25 6.71 137.65 6.7 137.45
75.30 4.3 75.65 4.2 74.84
60.87 4.2 60.93 4.17 60.97
53.96 4.0 48.62 3.96 54.30
48.37 4.19 54.41 4.12 48.79
82.11 3.44 82.45 3.36 82.36
30.35 2.77 29.84 2.7 29.74
30.35 2.44 29.84 2.38 29.74
23.12 1.86 21.33 1.97 22.83
26.11 1.54 25.91 1.5 26.14
25.63 1.49 25.34 1.46 25.49
14.06 1.27 14.11 1.28 13.96
9.38 0.93 8.47 0.89 9.43
9.133 0.88 8.20 0.86 9.01
129.27 129.20 128.49
171.39 172.50 172.28
165.88 167.84 165.93
170.68 168.75 168.41
23.12 126–137 4.41 59.90
7.4–7.8 2.0 24.18
1.93 29.74
3.44 46.17
8.0 6.97
8.3 7.99
10.92
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40,000 rpm for 2 h. The drug concentration in the supernatant was
determined by measuring the optical density of the drug molecules
and the amount of drug bound to liposomes was determined from the
difference. The drug-liposome apparent binding constant (K) was
analyzed using the double reciprocal plot. A plot of 1/(fraction bound)
vs. 1/[lipid concentration] yields a straight line with slope 1/K.
2.6. TEM experiments
TEM experiments were performed on a Carl Zeiss Libra 120 EF TEM
(Germany) with a LaB6 emitter and 120 kV accelerating voltage. LipidFig. 2. Themost favored poses of (A) oseltamivir (GS-4071) and (B) zanamivir (GG-167)
in the H5N1-NA active site as seen by docking studies (reprinted from reference [16]).
H-bonds between the drug and the enzyme are indicated.samples were deposited on Formvar®-carbon coated copper grids
(FCF400-Cu, Electron Microscopy Sciences, Hatﬁeld, PA) and allowed
to equilibrate. Excess liquid was removed with a ﬁlter paper and the
grid was air-dried.
2.7. Computational studies
Computational studies were carried out with the modeling
package Discovery Studio 2.0 (Accelrys Inc., USA) [26] running on a
Red Hat Enterprise Linux WS Workstation. Docking studies were
carried out with GOLD v 3.2 (CCDC, UK) [27] running on a separate
Red Hat Enterprise Linux WS Workstation.
2.7.1. Preparation of enzyme and ligand for docking
The crystal structure of the enzyme H5N1-NA in complex with
oseltamivir (GS-4071)was taken fromtheprotein data bank (PDB code
No. 2HU4, H252Y mutant) [28]. When analyzed within a 10 Å region
fromthe locusof the ligand, all active site residues are seen to reside ina
single monomeric unit of the enzyme. Therefore, only the monomeric
unit of the enzyme (an octamer of 8 chains) was used for docking
studies. The mutated residue tyrosine was changed to histidine
(H252Y). All the water molecules present in the crystal structure
were deleted and hydrogens to all atomswere added corresponding to
pH 7. The system was reﬁned using the CHARMm forceﬁeld with the
backbone atoms tethered by a force constant of 10 kcal/mol/Å, to a
gradient of 0.1 kcal/mol/Å. The structure of oseltamivir and its
derivatives were energy minimized to a gradient of 0.01 kcal/mole/Å
with the “Smart Minimizer”method in DS 2.0. This method carries out
both steepest descents and conjugate gradientsminimizationwith the
CHARMm force ﬁeld to reach the speciﬁed gradient.
2.7.2. Docking studies
The following parameters in GOLD were permitted to change
during the docking runs: the dihedral angles and ring geometries of
inhibitors, the dihedral angles of OH and NH2 groups of enzyme and
mappings of the H-bonds between the inhibitor and enzyme. At the
start of a docking run, all these variables were randomized. Docking
was carried out for 20 genetic algorithm (GA) runs, which was found
sufﬁcient to reproduce the binding pose of GS-4071 in 2HU4. Most of
the other GA parameters like population size and the genetic
operators were left at their default values. The binding site was
deﬁned by a sphere of 10 Å radius around the inhibitor. The docking
protocol was validated by the reproduction of the binding pose of GS-
4071 in 2HU4. A similar protocol was then used to dock zanamivir
(GG-167), GS-4071 and its derivatives, to H5N1-NA to determine their
preferred binding orientations. The docked poses were scored using
GoldScore. Hydrogen bonds formed between the molecules and the
residues in the active site of H5N1-HA were analyzed. Poses were
segregated and ranked on the basis of the GoldScore.
2.8. Synthesis of derivatives of oseltamivir
For the synthesis of various derivatives, oseltamivir phosphate was
ﬁrst dephosphorylated to obtain the drug with the free amino group.
2.8.1. Synthesis of OS-gly and OS-pro derivatives
Scheme 1 shows the general route for the synthesis of OS-gly
and OS-pro derivatives. Boc-glycine (0.560 g, 3.20 mM) or Boc-
proline (0.689 g, 3.20 mM), DCC (0.660 g, 3.19 mM) and the
catalyst N-hydroxybenzotriazole (0.150 g, 1.11 mM) were dissolved
in CHCl3 and stirred for 1 h at 0 °C. A solution of oseltamivir in
chloroform (1.0 g, 3.20 mM) was then added to this solution and
stirred for about 2 h at 0 °C and then for an additional period of
20 h at room temperature. The reaction mixture was ﬁltered to
remove the byproduct dicyclohexylurea (white precipitate) and the
ﬁltrate was evaporated under vacuum to yield an oily residue that
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washed successively with 10% aqueous citric acid solution, 4%
NaHCO3 solution and ﬁnally with water. Evaporation of the ethyl
acetate then gave an oily residue. Addition of a mixture of ether
and petroleum–ether helped to produce a white powder. The Boc
protecting group was removed by stirring the derivative in a
mixture (1:1) of triﬂuoroacetic acid (TFA) and methylene chloride
(CH2Cl2) for 1 h at 0 °C. The TFA and CH2Cl2 were then removed
by evaporation and the oily residue on stirring with ether and
petroleum–ether mixture yielded a solid residue. The purity of the
product was checked with TLC and the product was recrystallized
from water–ethanol mixture. The yield was 80% for both OS-gly
and OS-pro derivatives. The amide linkage thus formed in both
derivatives is a stable covalent bond. The purity of the two
compounds was further checked by NMR and HPLC.Fig. 3. Favored docking poses of derivatives in the H5N1-NA a2.8.2. Synthesis of OS-bz
2 ml of benzoyl chloride (140.56 mg, 17.2 mM) was added
dropwise to a solution of oseltamivir (1.0 g, 3.20 mM) in 20 ml
NaOH. The reaction mixture was shaken vigorously for 15–20 min
until a solid residue was obtained. The product was separated by
ﬁltration and repeatedly washed with water, dil. HCl and ﬁnally
with water. The solid was recrystallized from water–methanol
mixture. The purity of the product was checked by TLC and HPLC
and its structure was determined by NMR, showing the formation
of a stable benzoyl derivative. The yield of the product was 70%.
2.8.3. Synthesis of OS-ac
2 ml of acetyl chloride (78.49 mg, 28.30 mM) was added
dropwise to a solution of oseltamivir (1.0 g, 3.20 mM) in 10 ml
acetone (Scheme 2). The reaction mixture was stirred for aboutctive site (A) OS-gly (B) OS-ac (C) OS-pro and (D) OS-bz.
Table 2
Results of docking studies of oseltamivir (GS-4071) with H5N1-NA.
Amino
acid
residues
of
H5N1-NA
Ligands
Oseltamivir
(GS-4071)
Zanamivir
(GG-167)
OS-gly OS-ac OS-bz OS-pro
ARG118 HO–CfO....
HN
HO–
CfO....
NH
bz–
CfO....HN
GLU119 NH2....OfC CH2–
NH2....
OfC
ASP151 NH2....OfC NH2....OfC OfC–
NH....OfC
OfC–
NH....
OfC
bz-
CONH....
OfC
bz-
CONH....
OfC
ARG152 HN–CfO....
HN
HN–CfO....
HN
HN–
CfO....HN
OfC–
NH....NH
OfC–
NH....NH
ARG156 CH2–
NH2....HN
TRP178 NH2....OfC CH2–
NH2....
OfC
GLU227 NH2....OfC
GLU276 C–OH....OfC
C–OH....OfC
ARG292 HO–CfO....
HN
HO–CfO....
HN
HO–
CfO....HN
OfC–
OH....HN
HO–
CfO....
HN
HO–CfO....
HN
HO–
CfO....HN
TYR347 HO–CfO....
HO
OfC–OH....
HO
HO–
CfO....HO
OfC–
OH....HO
HO–
CfO....
HO
ARG371 OfC–OH....
HN
OfC–OH....
HN
OfC–
OH....HN
OfC–
OH....HN
OfC–
OH....HN
HO–CfO....
HN
HO–CfO....
HN
HO–
CfO....HN
HO–
CfO....
HN
HO–
CfO....
HN
TYR406 OfC–
NH....OH
H-bonds 8 11 10 8 4 4
Atoms involved in hydrogen bonding from ligands (row) to amino acid residues of
H5N1-NA (column) are underlined. Last row shows number of hydrogen bonds
observed in case of each ligand.
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precipitated out. The product was separated by ﬁltration and
washed well with cold water. The product was recrystallized from
water–methanol mixture. The yield of the product was 70%. The
purity of the product was checked by TLC and HPLC and its
structure was determined by NMR which showed the formation of
a stable acetyl derivative. The purity of the synthesized molecules
was checked by HPLC and was in the range of 88%–96%.
The atom of oseltamivir and its derivatives have been labelled in
Fig. 1 to aid the discussion of the 1H and 13C NMR resonance
assignments. The 1H and 13C resonances have been assigned using the
2D-COSY, DEPT (Distortionless Enhancement by Polarization Transfer)
[29] and HSQC (Heteronuclear Single Quantum Coherence) [30]
spectra and the assignments are given in Table 1.
2.9. LogP calculation
Hydrophobicity/hydrophilicity of the drug inﬂuences the beha-
vior of a molecule in a living organism, affecting its bioavailability,
transport, reactivity, toxicity, metabolic stability and many other
properties. We have therefore calculated the logP for oseltamivir-
GS-4104 (OS), its derivatives and zanamivir using VG method in
Marrin Sketch Version 5.2 of ChemAxon software, The values are:
zanamivir (−3.98), OS (−0.72), OS-gly (−0.66), OS-ac (1.05), OS-
bz (2.79) and OS-pro (1.05). Thus the hydrophilicity of these
molecules decreases in the following order. ZanamivirNOS≥OS-
glyNOS-pro=OS-acNOS-bz.
3. Results and discussion
3.1. Docking
The poses of oseltamivir (GS-4071) and zanamivir (GG-167) in
the active site of neuraminidase obtained by docking are depicted
in Fig. 2A and B respectively. The corresponding images for
oseltamivir derivatives are shown in Fig. 3A–D. Hydrogen bonds
seen between the derivatives and the amino acids in the H5N1-NA
active site have been recorded in Table 2. From the table it can be
seen that compared to oseltamivir, zanamivir forms additional H-
bonds which arise from the guanidino group with Trp178 and
Glu227 in H5N1-NA. Further, the OS-gly analog forms H-bonds
with Glu119 and Asp151 of H5N1-NA (similar to oseltamivir) and
also interacts with Trp178 (similar to zanamivir). The glycyl group
appended to the amino functionality in the OS-gly derivative
contributes additional H-bond interactions over the parent drug.
These additional H-bond interactions are responsible for the tighter
binding of the OS-gly analog with the neuraminidase enzyme, and
this might contribute to a lower susceptibility to resistance, in
parallel with the observation for zanamivir. Similar interactions
with Trp178 and Glu227 are not observed in the case of the OS-ac
analog; instead the acetyl group interacts with Asp151 and Arg152.
In the case of the OS-bz and OS-pro derivatives it is observed that
the bulky benzoyl and proline moieties show close van der Waals
contacts with Val149, Thr148, Thr439, Gln136 and Glu227, Trp178,
Arg156, Asp151 respectively. It is observed that strong steric
interactions of these bulky groups with the receptor surface
changes the overall 3D orientation of these molecules within the
receptor cavity. The docking results thus indicate that the addition
of bulky groups at the amino moiety in oseltamivir lowers the
afﬁnity for the neuraminidase enzyme and thus lead to a decrease
in the biological activity.
3.2. Binding studies with MLVs
The fraction of oseltamivir and its derivatives bound to lipid in
increasing concentration is shown in Supplementary Fig. 1 (S1). Fromthe logP values, it is anticipated that the greater the hydrophobicity
the higher would be the afﬁnity of the molecules for the lipid vesicles.
However, it is observed that in the case of OS and OS-gly nearly 60%
and 50% respectively of the total drug is bound to the liposomes even
at the relatively low lipid concentration of 0.5 mM. On the other hand,
for the more hydrophobic molecules (OS-ac, OS-pro and OS-bz) the
bound fraction is very low (5–10%). A plot of the inverse of the fraction
of drug bound vs. the inverse of the lipid concentration is linear.
The apparent binding constants are oseltamivir (OS) — 8594 M−1,
OS-gly — 3725 M−1, OS-ac — 623 M−1, OS-bz — 717 M−1 and OS-
pro— 187 M−1. These results indicate that these molecules do bind to
the MLVs and their binding afﬁnity increases with increasing
hydrophilicity. This is due to a preferential binding to the head
group (polar, hydrophilic portion) of the lipid vesicles, rather than the
more hydrophobic tail of the lipid.
Having determined that these molecules bind to the liposomes
with variable degree of afﬁnity (high to low), we address in
the following sections, the issues concerning the nature of this bin-
ding with regard to the thermotropic behavior and dynamics of
the lipid, and also the various groups involved in the intermolecular
interactions.
Fig. 4. DSC plots of DPPC (50 mM) incorporated with oseltamivir phosphate (GS-4104) (A), OS-gly (B), OS-ac (C), OS-bz (D) and OS-pro (E). The additives: lipid molar ratios are (a)
0:100, b) 1:10, c) 1:5, d) 1:2, and e) 1:1.
Table 3
Change in pre and main transition temperatures, ΔTm-pre (I) and ΔTm-main (II) on
addition of oseltamivir (GS-4104) and derivatives into DPPC bilayers.
Drug:lipid Oseltamivir OS-gly OS-ac OS-bz OS-pro
I II I II I II I II I II
1:100 1.34 0.34 3.05 0.85
1:10 2.78 0.87 2.95 0.81 1.98 0.0 2.06 0.0 7.49 1.96
1:5 3.86 0.96 2.68 0.60 – 0.06 – 0.0 – 1.13
1:2 – 2.66 – 2.91 – 0.89 – 1.53 – 1.22
1:1 – 3.8 – 3.08 – 0.67 – 3.51 – –
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3.3.1. Effect of oseltamivir on DPPC bilayers
The thermotropic aspect of drug–lipid interaction can be studied
with DSC by examining the changes in the melting point (Tm) and the
shape of the DSC trace [31]. Fig. 4 shows DSC curves of DPPC carrying
with varying concentrations of oseltamivir (GS-4104). The multi-
lamellar bilayers of plain DPPC show a pretransition at 33.74 °C and a
main transition at 41.34 °C due to the mobility of the polar choline
head group and the alkyl chain respectively [Fig. 4(a)]. On adding
various concentrations (from 0.5 mM to 50 mM) of GS-4104 into the
DPPC bilayer [Fig. 4A(b–e)], both the transition temperatures shift to a
lower value (at a drug concentration of as low as 1:100) and the peaks
broaden thereafter (Table 3) with the appearance of a shoulder peak
(Tm1). Subsequently, the pretransition peak completely vanishes
(broadened nearly to the baseline) and at a 1:1 molar ratio, the
main transition shifts to a still lower value by 3.8 °C and the shoulder
peak becomes a prominent peak [Fig. 4A(e)]. The intensity of this new
peakwhich corresponds to a new phase, increases with increasing GS-
4104 concentration. The Tm and Tm1 transitions, thus observed may be
due to the coexistence of GS-4104-rich and GS-4104-poor DPPC
domains (phases) within the bilayer [16]. The presence of coexisting
phases indicates phase segregation [32], which may arise from
osmotic stress on the DPPC bilayer, this stress may result from the
strong interaction of the phosphate group in GS-4104 with the polar
head group of the lipid. This is supported by studies on free GS-4104
(phosphate group absent) where the shoulder peak noted above
(indicative of phase segregation) is absent at all concentrations of the
free base [16].
3.3.2. Effect of OS-gly on DPPC bilayers
Fig. 4B shows the DSC curves of DPPC bilayers incorporated with
OS-gly at different concentrations. With increasing concentration of
OS-gly, both the pretransition peak as well as the main transition peak
broaden and shift to a lower temperature (Table 3), while the shape of
the endotherm remains symmetric. At higher concentration (1:1
molar ratio) the pretransition peak broadens whereas the main
transition peak shifts by 3.8 °C to a lower value being coupled withsigniﬁcant broadening. These changes are similar to that observed for
GS-4104 (OS) indicating that the endothermic behavior of OS-gly
parallels that of GS-4104 (OS).
3.3.3. Effect of OS-ac, OS-bz and OS-pro on DPPC bilayers
The addition of OS-ac to DPPC bilayers (Fig. 4C) causes little change
to both the pretransition and main transition temperatures (Table 3).
However, the extent of broadening of both peaks is greater compared
to GS-4104 (OS) and OS-gly. On the other hand, attaching a benzoylic
group (OS-bz) or prolyl moiety (OS-pro) to oseltamivir leads to
remarkable changes in the DSC isotherms of the DPPC bilayer (Fig. 4D
and E). In the case of OS-bz, with increasing concentration, both the
pretransition as well as the main transition peaks shift to lower
temperature along with a broadening of the peaks; ﬁnally multiple
peaks begin to appear (Fig. 4D). In the case of OS-pro, even at a low
concentration (1:10), the pretransition peak broadens considerably
with a simultaneous large shift (7.49°) in the transition temperature
(Table 3). With increasing OS-pro concentration, the shift in the main
transition temperature is not large as compared to the pretransition
peak (Fig. 4E). However, the peak broadens and ﬁnally breaks into
multiple peaks at a 1:1 molar ratio. Similar broadening and multi-
plicity has been observed for a 1:5 molar ratio on repeating the
experiment after two days (ﬁgure not shown). These results indicate
that the addition of a bulky group (benzoyl or prolyl) leads to a large
perturbation and disruption of the DPPC bilayers compared to that
seen with the smaller glycyl and acetyl groups in OS-gly and OS-ac
respectively and also for the unmodiﬁed drug GS-4104 (OS).
Fig. 5. 125.7 MHz 13C NMR spectra of (A) oseltamivir phosphate (GS-4104) (OS)
(10 mM) in D2O (G) DPPC (50 mM) unilamellar vesicles, (B–F) OS, OS-gly, OS-ac, OS-bz
and OS-pro, respectively, incorporated into DPPC unilamellar vesicles (1:5 additive:
lipid molar ratio). d in each spectrum indicates signals arising from different additives.
All experiments are at 323 K.
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3.4.1. 13C NMR
To probe deeper into the nature of the intermolecular interaction
between oseltamivir (GS-4104) and its derivatives with the lipid
membrane, 13C NMR experiments have been carried out for GS-4104
and its derivatives alone and in presence of the lipid bilayers (Fig. 5).
The 13C NMR spectra of GS-4104 and its derivatives are nearly identical
except for the signals that appear due to the substituent (glycyl, acetyl,
benzoyl and prolyl). The assignments have been made using the DEPT
spectrum [29] and from themultiplicity pattern of the resonances. The
13C NMR spectrum of the DPPC bilayer has been assigned as reported
in the literature [33].
The spectra of plain DPPC bilayers (Fig. 5G), GS-4104 (Fig. 5A) and
its derivatives are characterized by sharp signals. In the case of GS-
4104, OS-gly and OS-ac incorporated into lipid bilayers (Fig. 5B–D)
most of the drug signals and the lipid resonances remain sharp (e.g. d
in Fig. 5B) indicating fast exchange between bound and free form.
However, in the case of OS-bz and OS-pro on incorporation into lipid
bilayers, all the signals are completely broadened (compared to the
pure form) (Fig. 5E and F respectively). The broadening of the signals
arises due to an exchange at intermediate time scale between the
bound and the free form of these derivatives. Due to the broad nature
of the signals it is not possible to measure both the spin lattice
relaxation time (T1) and the spin–spin relaxation time (T2) which is ameasure of the overall tumbling behavior and segmental motion of
the molecule. In the fast tumbling range, both T1 and T2 are large, of
the order of a few seconds [34]. The estimate of T2 from the line
widths which is about 100 ms indicates that the molecules lose their
mobility and become strongly bound to lipid bilayers resulting in a
loss of motional freedom. This also indicates an increase in the
motional ordering of the lipid acyl chain and the head group. However,
a few signals which remain relatively sharp indicate the mobility of
the respective atoms. The results thus indicate that the binding of
these molecules to DPPC is greatly dependent on the nature of the
derivative. OS-gly and OS-ac show an average binding characteristic
like GS-4104 where the molecules are in a free motion/fast exchange,
with most of the signals continuing to remain sharp. On the other
hand, in the case of OS-bz and OS-pro, the molecules are strongly
bound to the lipid bilayer and loose their motional freedom, as
indicated by a complete broadening of the signals.
3.4.2. 2D NOESY
The 2D NOESY spectrum contains a wealth of information on
intermolecular interactions as well as the conformation (from
intramolecular NOEs) of the molecules in the lipid bilayer. The
NOESY spectrum of oseltamivir (GS-4104) incorporated into DPPC
unilamellar vesicles is shown in Fig. 6. The assignments for GS-4104 are
indicated in the ﬁgure along the F2 dimension and the intermolecular
NOEs are indicated in the F1 dimension. The intermolecular NOE's seen
between the lipid and GS-4104 (OS), OS-gly, OS-ac, OS-bz and OS-pro,
respectively have been presented in Table 4. The data in Table 4 shows
that in the case of OS-gly and OS-pro [NOESY spectra of these
derivatives shown as inset Fig. 6(a and b)] a number of additional
intermolecular NOEs are seen compared to GS-4104; these additional
interactions are with the head group of the lipid, modifying the head
groupmotional freedom/ordering. In complete contrast, for the OS-bz
and OS-ac derivatives, the additional NOEs are between the benzoylic/
acetyl groups and the hydrophobic acyl chains of the lipid; the
interactions with the lipid head group are absent.
3.4.3. 31P NMR
31P NMR spectroscopy is sensitive to local motions and the
orientation of the phosphate group in the membrane [35], making it
well suited for monitoring structural changes and detecting poly-
morphism in model membranes [36]. The 31P NMR resonance line
shape is determined by the chemical shift anisotropy (CSA) of the
phosphate group coupled with the molecular motions near the head
groups [37].
The effect of OS (GS-4104) and its derivatives OS-gly, OS-ac, OS-bz
and OS-pro on the 31P NMR line shape was measured as a function of
concentration (Fig. 7a–d) as well as temperature (ﬁgure not shown).
The build up of a sharp peak at 0 ppmwith increasing concentration, is
due to the PO42− group present in OS [Fig. 7(I)]. With increasing
concentration of OS, the characteristic feature of the bilayer (presence
of both the parallel and perpendicular components) remains
unchanged. However, in the presence of relatively high concentration
of drug, the width of the 31P resonances is narrower and there is a
small change in the CSA parameter as seen by the sharpening of the
parallel component at−20 ppm. This is due to the increasedmotional
freedom/decreased order of the phospholipid head group. Overall,
this seems to indicate that OS (GS-4104) stabilizes the lipid bilayer
phase [38,39]. Studies on cylosporin A and other drugs have shown
that stabilization of the membrane by antiviral drugs can play an
important role in inhibiting membrane fusion and also antiviral
activity [40]. Therefore, GS-4104 seems to be involved in preventing
membrane fusion in addition to inhibition of NA activity.
On incorporation of varying concentrations of OS-gly [Fig. 7(II)], the
31P NMR line shape is not affected and remains very similar to the pure
DPPC bilayer (a). The features of the structure of the bilayer as seen in
the line shape remainunchangedwhich is similar toGS-4104.However,
Fig. 6. 2D NOSEY spectrum of DPPC unilamellar vesicles incorporated with oseltamivir phosphate (GS-4104) (1:5 GS-4104: lipid molar ratio). The experiment was carried out with a
mixing time of 250 ms. Inset (a) shows the spectrum of OS-gly incorporated into DPPC unilamellar vesicles (1:5 molar ratio). Inset (b) shows the spectrum of OS-pro incorporated
into DPPC unilamellar vesicles (1:5 molar ratio). All experiments are at 323 K.
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and the main peak at−20 ppm also broadens to a very large extent at
1:5 OS-ac:lipid ratio. This increase in CSA indicates the formation of
even larger vesicles. However, the bilayer features remain intact to a
large extent keeping the vesicles highly rigid [the spectral features
compare very well to the low temperature (20 °C) spectrum]. This
suggests that OS-ac causes very little perturbation of the bilayer. In the
case of the OS-bz analog, with increasing concentration the peak at
0 ppm becomes sharper and increases in intensity. The main peak at
−20 ppm decreases in intensity with ensuing broadening [Fig. 7(IV)].
This is characteristic of the transformation of the bilayer phase to the
hexagonal phase [41]. On theotherhand, in the case ofOS-pro, thepeakTable 4
NOE's observed in the NOESY spectra of DPPC unilamellar vesicles incorporated with
oseltamivir (GS-4104) and its derivatives.
DPPC Oseltamivir
(GS-4104)
OS-gly OS-ac OS-bz OS-pro
CH3 CH2(11,13), CH3
(12,14)
CH2(11,13),
CH3(12,14)
CH2(11,13),
CH3(12,14)
CH2(11,13),
CH3(12,14)
CH2(11,13),
CH3(12,14)
(CH2)n CH2(11,13), CH3
(12,14), CH(6)
CH2(11,13),
CH3(12,14),
CH(6)
CH2(11,13),
CH3(12,14),
CH(6)
CH2(11,13),
CH3(12,14),
CH(6)
CH2(11,13),
CH3(12,14),
CH(6)
CH(10) – CH3(18) CH(19–23) –
CH(B) CH2(8) CH2(8) – – CH2(8), CH
(3), CH2(18)
CH2(β) CH(2) – – – –
N(CH3)3 CH2(8) CH2(18) – – CH2(8), CH2
(18), CH(10),
CH2(21)at 0 ppm increases in intensity and the peak at −20 ppm splits into
sharpmultiplepeaks [Fig. 7(V)]. Themultilamellar bilayerphase is thus
completely disrupted with the breaking of the multilamellar vesicles
into nearly hexagonal rods. These results thus indicate that the two
derivatives OS-bz and OS-pro lead to a complete transformation of the
original multilamellar bilayer phase with decreased motional free-
dom/enhanced acyl chain ordering.
3.5. TEM
TEM has evolved as an important tool to gain new information on
the form and structure of liposomes, as well as on the morphological
changes taking place upon interaction with drugs, surfactants, DNA
and other polyelectrolytes [42]. In order to support the stabilization of
the lipid bilayer phase by GS-4104 as seen by NMR and DSC, we have
studied the phase behavior and the aggregate structure of the
liposomes with TEM. Fig. 8(A–F) shows electron micrographs of
DPPC dispersions alone and in the presence of OS (GS-4104), OS-gly,
OS-ac, OS-bz and OS-pro (1:5 drug:lipid molar ratio). It is observed
that pure DPPC dispersions show the characteristic bilayer features of
large vesicles (Fig. 8A). On addition of GS-4104 the bilayer
characteristics of the lipid dispersions are largely retained and no
polymorphism is observed (Fig. 8B). Moreover, there is an absence of
any fusion bodies in the micrograph. This is in contrast to the studies
with the fusogenic drug piroxicam which is seen in TEM micrographs
to induce membrane fusion [43] when compared to the control
sample of DMPC dispersions.
A similar behavior is observed for OS-gly (Fig. 8C). However OS-ac
shows a mixed feature with the formation of relatively large
structures. On the other hand OS-pro and OS-bz completely disrupt
Fig. 7. 202.4 MHz 31P NMR spectra of DPPC (100 mM) multilamellar vesicles incorporated with (I) oseltamivir phosphate (GS-4104) (OS), (II) OS-gly, (III) OS-ac, (IV) OS-bz and (V)
OS-pro. The additives: lipid molar ratios are (a) 0:100, (b) 1:5, (c) 1:2, and (d) 1:1. All experiments are at 323 K.
Fig. 8. Transmission electron microscope (TEM) picture of DPPC multilamellar vesicles
(A) and incorporated with oseltamivir phosphate (GS-4104) (OS) (B), OS-gly, (C) OS-ac,
(D), OS-bz (E) and OS-pro (F) in 1:5 additive: lipid ratio.
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characteristic micrograph (Fig. 8D and E).
These results thus indicate that GS-4104 and OS-gly bind to the cell
membrane in such away that they stabilize the bilayer character of the
membrane and thus prevent the cell–cell fusionwhich is an important
phenomenon during the viral entry in the host cell [44–46].
4. Discussions
The H5N1-NA active site consists of four well-conserved binding
sites with 11 functional residues which participate in the catalytic
reaction [47,48]. These are the positively charged site-1 (Arg118,
Arg292 and Arg371), the negatively charged site-2 (Glu119, Glu227
and Asp151), site-3 (Ile222 and Tyr178), and site-4 (Glu276 and
Glu277). Moreover presence of the 150 loop (residues 147–152),
adjacent to the active site leads to the formation of closed and open
conformations, enabling binding to inhibitors [28].
The docking results indicate that increasing the molecular volume
of GS-4071 by adding substituents on the amino group, changes the
intermolecular interaction to a large extent. The strength of this
interaction depends on the size of the substituent. Addition of a small
group such as glycyl with its amino group charged at physiological pH
enhances the interaction with the receptor site and will possibly
increase its inhibitor activity. On the other hand bulky groups like
proline and benzyl are not suitable substituents, as these groups bump
into the receptor surface, shifting the locus of the binding, and will
probably lead to a lower activity. Thus for improvement in antiviral
activity, the introduction of functional moieties at the amino group,
with proper shape; size, electronic charge and lipophilicity is critical.
The pretransition temperature of lipid bilayers is very sensitive to
the presence of impurities anddisappears evenwith small quantities of
impurities [49]. In the case of lipid bilayers incorporated with GS-4104
and its derivatives OS-gly and OS-ac, the pretransition peak remains,
but shifts to a lower temperature. There is a good indication from the
NMRexperiments that thesemolecules interactwith the head group in
a manner that stabilizes the membrane architecture to a large extent.
Secondly, a decrease in the main transition temperature indicates that
they impartﬂuidity to the bilayer bypositioning themselveswithin the
hydrophobic core. The bilayer structure is retained in these three cases
except for a slight perturbation by OS-ac. These observations are
further supported by a recent DSC study where both cholesterol and a
peptide were shown to reduce the Tm markedly and stabilize the ﬂuid
phase of themembranes [50]. On the other hand, the derivatives Os-bzandOS-pro showanomalous behavior, perturbing the bilayer structure
completely by disturbing the stronghydrophobic interactions between
the lipid molecules. This leads to the formation of small pools of
structures giving rise to multiple peaks in the DSC spectrum and
simultaneous variation in the Tm of the DSC curves [51]. The observed
effectmaybedue to the insertionof these groups into the phospholipid
bilayers in order to maximize the van der Waals interactions. The 31P
NMR results support the above quoted DSC results.
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lipid bilayers does not disturb the bilayer phase of the multilamellar
vesicles. A similar effect has been reported, where the characteristic
broad spectrum and the low ﬁeld shoulder of the bilayer phase
persist even at higher temperatures in the presence Z-fFG (virus
replication inhibitory peptide) and amantadine [40]. OS-ac although
causing no overall changes to the bilayer characteristics, changes the
motional rigidity of the vesicles. This is evident from the spectral
features which indicate enhanced CSA and increase in the size of
the vesicles. On the other hand OS-bz and OS-pro perturb the
bilayer phase completely, disrupt the multilamellar structure,
causing appearance of the hexagonal phase. The results are further
supported by 13C and NOE data where the intermolecular interac-
tions in the case of GS-4104 and its derivatives can be categorized as
weak for GS-4104 and OS-gly, moderate for OS-ac and strong for the
OS-bz and OS-pro derivatives. Moreover, it is evident from the NOE
data that GS-4104 and OS-gly show preferential binding to the head
group as compared to OS-bz and OS-pro, which reside closer to the
hydrophobic core. These results agree with the logP values
indicating that the hydrophilicity of the molecules plays an
important role whereby the most hydrophilic molecule like OS-gly
binds to the head group and stabilizes the membrane from fusion as
compared to OS-bz. Further, it may be noted that substances which
occupy a position near the surface of the bilayer can inhibit the
formation of the hexagonal phase, as well as inhibit membrane
fusion phenomenon [52].
5. Conclusions
Stabilization of the membrane by antiviral drugs can play an
important role in inhibiting membrane fusion and also in their
antiviral activity [40]. Viral induced cell–cell fusion is known to be
inhibited by cyclosporin A, which is also known to stabilize the bilayer
phase of membranes [53]. OS-gly like GS-4104 prevents membrane
fusion and is seen to have a stabilizing effect on the membrane. OS-ac
causes marginal disruption of the lipid bilayers. The other two
compounds, OS-pro and OS-bz are identical in their action, disrupting
the bilayer structure. On the basis of these results, we conclude that of
the four derivatives, OS-gly is the most promising candidate for
further in vivo/in vitro pharmacological evaluation.
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